4
Changes in Ownership
Aclaris Therapeutics, Inc. Filed Acc 0001209191-22-015809
Chief Financial Officer acquired 42,347 shares (option exercise)
From the SEC's structured data for this filing
Trades in this filing
| Insider | Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|---|
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Option exercise | +25,750 | 198,109 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Option exercise | +8,300 | 206,409 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-02 | Option exercise | +8,297 | 214,706 | D | ||
| Derivatives | |||||||
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Grant or award · Employee Stock Option (Right to Buy) | +155,200 | 155,200 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Grant or award · Restricted stock units | +44,300 | 44,300 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Option exercise · Restricted stock units | −25,750 | 25,750 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-01 | Option exercise · Restricted stock units | −8,300 | 24,900 | D | ||
| Ruffo Frank Chief Financial Officer | 2022-03-02 | Option exercise · Restricted stock units | −8,297 | 16,595 | D | ||
Loading xslF345X03/doc4.xml…